Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
S
Susan Panozzo
Researcher
Also affiliated: University of Arkansas Medical Center (2016); Winthrop Rockefeller Foundation (2023)
Faculty Researcher
6 h-index
30 pubs
446 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Susan Panozzo's research centers on the treatment and long-term outcomes of multiple myeloma. Her work involves analyzing data from clinical trials, including the "Total Therapy" protocols, to evaluate treatment efficacy and patient survival. Publications include investigations into maintenance therapy with VRD (bortezomib, lenalidomide, dexamethasone) and the impact of adding bortezomib and thalidomide to melphalan transplants for patients with adverse metaphase cytogenetics. Panozzo has a publication record of 30 works with 426 citations and an h-index of 6. She has collaborated with researchers at the University of Arkansas for Medical Sciences, including Clyde Bailey, Michele Cottler-Fox, Shmuel Yaccoby, and Erming Tian, on multiple shared publications.
Metrics
- h-index: 6
- Publications: 30
- Citations: 446
Selected Publications
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)
-
Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma (2023)
-
Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups (2019)
-
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma (2018)
-
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants (2016)
-
A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant (2015)
-
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib (2015)
-
Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM) (2014)
-
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma (2014)
-
Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma (2013)
-
Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity (2013)
-
Final Results Of Phase II Study Of Pomalidomide (Pom) In GEP-Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM) (2013)
-
Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM) (2012)
Collaboration Network
Top Collaborators
Samer Al Hadidi
University of Arkansas for Medical Sciences
4 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Obada Ababneh
The University of Texas MD Anderson Cancer Center (US)
4 shared publications
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Carolina Schinke
University of Arkansas for Medical Sciences
4 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
4 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Clyde Bailey
University of Arkansas for Medical Sciences
4 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
John D. Shaughnessy
University of Arkansas for Medical Sciences
4 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Maurizio Zangari
University of Arkansas for Medical Sciences
4 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Frits van Rhee
University of Arkansas for Medical Sciences
4 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Guido Tricot
University of Arkansas for Medical Sciences
3 shared publications
In database
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Daisy Alapat
University of Arkansas for Medical Sciences
3 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Bart Barlogie
University of Arkansas for Medical Sciences
3 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Fenghuang Zhan
University of Arkansas for Medical Sciences
3 shared publications
In database
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
Jeffrey R. Sawyer
University of Arkansas for Medical Sciences (US)
3 shared publications
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
Robert W. Smith
Winthrop Rockefeller Foundation (US)
2 shared publications
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma
Robert Smith
University of Arkansas for Medical Sciences
2 shared publications
In database
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
Similar Researchers
Based on overlapping research topics
Clyde Baily
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Amisha Fnu
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
O. Makhoul
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation
Monica L Grazziutti
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Health Disparities and Outcomes
Yarlagadda Lakshmi S
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Health Disparities and Outcomes
Sravani Gundarlapalli
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Hematopoietic Stem Cell Transplantation